Status:

RECRUITING

129Xe MRI Cardiopulmonary

Lead Sponsor:

Bastiaan Driehuys

Collaborating Sponsors:

National Institutes of Health (NIH)

Conditions:

Interstitial Lung Disease

Chronic Thromboembolic Pulmonary Hypertension

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.

Detailed Description

This study focuses on the markers that are derived from the interaction of 129Xe with pulmonary capillary red blood cells (RBCs). Specifically, the investigators focus on RBC transfer MRI, cardiogenic...

Eligibility Criteria

Inclusion

  • Inclusion Criteria for Healthy Volunteers:
  • (Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial)
  • Outpatients of either gender, age \> 18
  • Willing and able to give informed consent and adhere to visit/protocol (Consent must be given before any study procedures are performed.)
  • Subject has no diagnosed pulmonary conditions
  • Subject has not smoked in the previous 5 years
  • Smoking history, if any, is less than or equal to 5 pack-years
  • No history of using other inhaled products more than 1/week for \> 1 year
  • Inclusion Criteria for Transfusion and Phlebotomy Patients:
  • In-patient or outpatients of either sex, age \> 18
  • Willing and able to give informed consent and adhere to visit/protocol
  • And one of the following:
  • Patients who are scheduled to receive a red cell transfusion for anemia.
  • Patients who are scheduled to undergo therapeutic phlebotomy to treat erythrocytosis or polycythemia
  • Healthy volunteers undergoing voluntary whole blood donation (healthy volunteer inclusion criteria noted above)
  • Inclusion Criteria for Oxygen Administration Patients:
  • In-patient or outpatients of either sex, age \> 18
  • Willing and able to give informed consent and adhere to visit/protocol
  • And one of the following categories (ILD, Dyspnea, CTEPH, or Healthy):
  • Interstitial Lung Disease or Dyspnea
  • Physician diagnosis of Interstitial Lung Disease by a pulmonologist using established criteria or physician referral of patient with dyspnea
  • OR
  • Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
  • Patients with a diagnosis of CTEPH, defined as mean PA pressure \>20 mmHg with a pulmonary vascular resistance \>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation
  • Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans
  • OR
  • Healthy Volunteer (criteria noted above)
  • Inclusion Criteria for Acute or Chronic Pulmonary Embolism Patients:
  • In-patient or outpatients of either sex, age \> 18
  • Willing and able to give informed consent and adhere to visit/protocol
  • And one of the following categories (Acute or Chronic)
  • Acute Pulmonary Embolism
  • Patients presenting with acute PE 24-48hrs post-admission
  • Willing to return after 3-6 months of anti-coagulation therapy
  • OR
  • Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
  • Patients with a diagnosis of CTEPH, defined as mean PA pressure \>20 mmHg with a pulmonary vascular resistance \>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation
  • Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans
  • Exclusion Criteria for All subjects:
  • Subjects presenting with any of the following will not be included in the trial:
  • MRI is contraindicated based on responses to MRI screening questionnaire
  • Subject is pregnant or lactating
  • Resting O2 saturation \<90% with maximum supplemental O2 delivered by nasal canula
  • Respiratory illness of a bacterial or viral etiology within 30 days of MRI
  • Subject has history of any known ventricular cardiac arrhythmia
  • Subject has history of cardiac arrest within the last year
  • Subject does not fit into 129Xe vest coil used for MRI
  • Subject cannot hold his/her breath for 10 seconds
  • Subject deemed unlikely to be able to comply with instructions during imaging
  • Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements

Exclusion

    Key Trial Info

    Start Date :

    January 12 2024

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    June 30 2028

    Estimated Enrollment :

    125 Patients enrolled

    Trial Details

    Trial ID

    NCT06038630

    Start Date

    January 12 2024

    End Date

    June 30 2028

    Last Update

    February 27 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Duke University Medical Center

    Durham, North Carolina, United States, 27710